Iris Kamer

Ramat Gan, TA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts.

PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts.

Journal: Molecular medicine (Cambridge, Mass.)

Published: March 12, 2026

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

Journal: Cell reports. Medicine

Published: March 03, 2025

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing.

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing.

Journal: Molecular oncology

Published: November 10, 2024

CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis.

CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis.

Journal: Brain : a journal of neurology

Published: March 30, 2024

Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.

Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.

Journal: JCO precision oncology

Published: March 21, 2024

Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells.

Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells.

Journal: Cancer immunology research

Published: October 06, 2023

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection.

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection.

Journal: Biosensors

Published: April 14, 2023

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit.

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit.

Journal: Scientific reports

Published: August 23, 2022

Interferon-stimulated neutrophils as a predictor of immunotherapy response.

Interferon-stimulated neutrophils as a predictor of immunotherapy response.

Journal: Cancer cell

Published: August 19, 2022

The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.

The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.

Journal: Nature cancer

Published: May 30, 2022

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade.

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: May 09, 2022

Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.

Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.

Journal: Nature cancer

Published: February 07, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026